Form 4: Maravai LifeSciences Director Sean Cunningham Receives Significant Restricted Stock Unit Award

Maravai LifeSciences Holdings, Inc. Director Sean Laurence Cunningham was awarded 89,139 restricted stock units valued at $2.16 per share, vesting over one year or by the 2026 annual meeting.

Summary

• Sean Laurence Cunningham, a Director and 10% Owner of Maravai LifeSciences Holdings, Inc. (MRVI), reported an acquisition of Class A Common Stock.
• On June 16, 2025, Mr. Cunningham was awarded 89,139 restricted stock units (RSUs) under the company's 2020 Omnibus Incentive Plan.
• Each RSU was valued at $2.16, totaling approximately $192,540.24.
• These RSUs are set to vest in full upon the earlier of one year from the grant date (June 16, 2025) or the date of the 2026 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders.
• Following this transaction, Mr. Cunningham's reported beneficial ownership stands at 138,055 shares of Class A Common Stock.
• The reporting person holds these securities for the benefit of a GTCR-affiliated entity and disclaims any pecuniary interest, indicating indirect beneficial ownership despite the direct holding in the table.

Sentiment

Score: 7

Explanation: The award of restricted stock units to a director is generally a positive signal, indicating continued alignment of interests and commitment to the company's long-term performance. It's a routine compensation event, not indicative of distress or exceptional performance beyond the standard incentive structure.

Positives

• The award of restricted stock units to a director aligns management's interests with long-term shareholder value.
• The vesting schedule encourages retention and continued commitment from the director.

Future Outlook

The restricted stock units are designed to vest over the next year or by the 2026 annual meeting, indicating a future commitment period for the director.

Management Comments

• "The Reporting Person disclaims any pecuniary interest in the securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16."

Industry Context

This transaction is a routine insider compensation disclosure common in the life sciences industry, where equity awards are frequently used to incentivize and retain key personnel, including directors, aligning their interests with long-term company performance.

Comparison to Industry Standards

• The award of restricted stock units to a director is a standard practice for executive and board compensation across publicly traded companies, including those in the life sciences sector.
• While specific comparable companies or projects are not detailed in this filing, equity-based compensation like RSUs is a widely accepted mechanism to align director incentives with shareholder value creation, similar to practices observed at peers like Thermo Fisher Scientific (TMO) or Danaher Corporation (DHR) in their compensation structures, though the specific amounts and vesting terms vary by company size, performance, and individual roles.

Corporate Governance

Related Party Transactions

• Sean Laurence Cunningham, a Director and 10% Owner, received an RSU award. The shares are held for the benefit of a GTCR-affiliated entity, and Mr. Cunningham disclaims pecuniary interest. This arrangement highlights a connection between the director, the company, and a significant shareholder (GTCR), which is a common related-party structure in companies with private equity backing.

Stakeholder Impact

• Shareholders: The equity award aligns the director's interests with long-term shareholder value.

Next Steps

• Vesting of the restricted stock units will occur upon the earlier of June 16, 2026, or the date of the 2026 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders.

Key Dates

Keywords

Maravai LifeSciences, MRVI, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU, Sean Cunningham, Director Compensation, Equity Award, GTCR